PATENT CLAIM ANALYSIS

Application Number: 15751169
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
The present invention provides novel humanized anti-human CCR7 antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. The invention further provides nucleic acid molecules encoding the anti-CCR7 antibodies, cells expressing the anti-CCR7 antibodies and methods for producing the anti-CCR7 antibodies.

Claim (Index 26):
A method for treating a cancer, an inflammatory condition, a condition or complication arising from tissue or organ transplantation, or a condition or complication arising from or associated with fibrosis in a subject in need thereof comprising administering the pharmaceutical composition of  claim 24 .

Metadata:
- Claim Count in Document: 92.0
- Percentile: 88.0
- Lexical Diversity: 1.8
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15756043', '14673792', '15182327', '15399122', '15505064']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7083358379970655
- 35 USC 102 Novelty (BERT): 0.5424588030400965
- Combined Prediction Score: 0.6917481345013686
- Mean Citation Score: 378.784036
- Max Citation Score: 384.58862
- Similarity Product: 263.9197115905046

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test